Physician profile
Ellen Burov
NPI 1528146958
$16,688.67
in general payments reported to CMS, 2019-2025
26 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $326 · 2021: $5,243 · 2022: $3,136 · 2023: $2,967 · 2024: $2,392 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,977 · Food and Beverage: $2,112 · Education: $80.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,976.55 |
| Food and Beverage | $2,111.51 |
| Education | $80.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,001.47 | 2019-2023 | |
| Abbvie INC. | $5,203.49 | 2023-2025 | Botox |
| Merz North America, INC. | $448.74 | 2019-2023 | |
| Janssen Biotech, INC. | $353.36 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $217.94 | 2019-2025 | Aklief |
| Dermavant Sciences, INC. | $188.50 | 2023-2024 | Vtama |
| Amgen INC. | $185.48 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $151.29 | 2022-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $146.32 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $120.35 | 2024-2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $92.85 | 2019 | |
| Avion Pharmaceuticals | $86.84 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.82 | 2019-2022 | |
| Lilly USA, LLC | $71.67 | 2024 | Olumiant, Taltz |
| Journey Medical Corporation | $56.97 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.73 | 2025 | |
| Mission Pharmacal Company | $41.18 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.22 | 2019-2020 | |
| Genzyme Corporation | $31.37 | 2025 | |
| Ucb, INC. | $21.48 | 2023 | Cimzia |
| Evofem Biosciences, INC. | $20.67 | 2022 | |
| Dermira, INC. | $19.90 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.16 | 2023 | Cyltezo |
| Almirall LLC | $18.15 | 2019 | |
| Mayne Pharma Commercial LLC | $17.10 | 2019 | |
| Therapeuticsmd, INC. | $14.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Burov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.